Physician profile
Peter Martindale
NPI 1841505864
$2,682.19
in general payments reported to CMS, 2019-2025
21 companies · $792 in 2025
The $792 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $101 · 2021: $270 · 2022: $459 · 2023: $459 · 2024: $376 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $370.96 | 2022-2025 | Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $329.94 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $256.86 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $246.80 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $242.05 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $217.98 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $152.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $142.28 | 2021-2022 | |
| Harrow Eye, LLC | $125.22 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $119.19 | 2019-2023 | Cequa |
| Amgen INC. | $110.64 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $101.42 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $44.32 | 2019-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $38.83 | 2020-2021 | |
| Horizon Therapeutics Plc | $36.95 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $33.77 | 2021-2022 | |
| Astellas Pharma US INC | $31.94 | 2025 | Izervay |
| Sight Sciences, INC. | $23.63 | 2023 | Tearcare System |
| Eyevance Pharmaceuticals LLC | $20.89 | 2019 | |
| Coopervision INC. | $19.61 | 2021 | |
| Rxsight INC | $16.02 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Martindale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.